

Special Issue

Immunotherapies and Systems Medicine of Melanoma and Autoimmunity: Recent Advances and Challenges

Message from the Guest Editor

This Special Issue focuses on recent advances and challenges in melanoma immunotherapies and systems medicine of melanoma and autoimmunity. These include currently available strategies for the implementation of personalized immunotherapy, functional and clinical association analyses exploring how tumor heterogeneity (at the genome, transcriptome/proteome, and epigenome levels) affects the immune microenvironment, and cutting-edge delivery technologies for cancer immunotherapy. Of particular interest are studies providing mechanistic insights into the impact of immune therapeutics on adverse autoimmunologic events. In this Special Issue, we welcome a variety of submissions, including reviews and original research articles.

Guest Editor

Prof. Dr. Brigitte Pützer

1. Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057 Rostock, Germany
2. Department Life, Light and Matter, University of Rostock, 18059 Rostock, Germany

Deadline for manuscript submissions

closed (15 March 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/122816

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)